🇺🇸 cyclosporine ophthalmic emulsion in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 15

Most-reported reactions

1. Vision Blurred — 4 reports (26.67%)
2. Dizziness — 2 reports (13.33%)
3. Eye Irritation — 2 reports (13.33%)
4. Abdominal Discomfort — 1 report (6.67%)
5. Asthma — 1 report (6.67%)
6. B-Cell Lymphoma — 1 report (6.67%)
7. Bronchial Neoplasm — 1 report (6.67%)
8. Bursitis — 1 report (6.67%)
9. Carpal Tunnel Syndrome — 1 report (6.67%)
10. Chronic Myeloid Leukaemia — 1 report (6.67%)

Source database →

Frequently asked questions

Is cyclosporine ophthalmic emulsion approved in United States?

cyclosporine ophthalmic emulsion does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for cyclosporine ophthalmic emulsion in United States?

Vanderbilt-Ingram Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.